New drug aims to protect transplanted kidneys

NCT ID NCT06059664

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether finerenone, a drug already used for kidney disease, can help protect transplanted kidneys. About 100 adults who received a kidney transplant 1 to 10 years ago will take either finerenone or a placebo daily for 12 months. Researchers will check how well the drug is tolerated and whether it improves kidney health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finerenone (Kerendia) oral tablet
What this could lead to: If successful, finerenone could become a new option to protect kidney function and reduce damage in transplant recipients, potentially delaying graft failure.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not apply broadly. Finerenone can raise potassium levels, requiring careful monitoring and dose adjustments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

UNC Eastowne Kidney Transplant Clinic
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.